Status:
TERMINATED
Metformin for Weight Loss in Schizophrenia
Lead Sponsor:
Nathan Kline Institute for Psychiatric Research
Conditions:
Schizophrenia
Obesity
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Study hypothesis is that patients on antipsychotics medication treated with metformin will show loss in weight and improved measures of glucose metabolism.
Detailed Description
Patients who had gained more than 10 lbs of weight in the last 3 months or had BMI of 35 or greater were treated with metformin up to 2500 mg/day in an open label study of up to 3 months time. Changes...
Eligibility Criteria
Inclusion
- Patients will be 18-70 years of age;
- Currently hospitalized or an outpatient at MPC;
- BMI ≥ 35 or excessive recent weight gain ( \> than 10 lb weight gain in the past 3 months);
- Patients will have a diagnosis of schizophrenia or schizoaffective disorder or bipolar disorder.
Exclusion
- Age below 18 or over 70;
- Patient is currently already treated with metformin.
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01177709
Start Date
May 1 2008
End Date
April 1 2011
Last Update
September 1 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Manhatan Psychiatric Center
New York, New York, United States, 10035